Yifang Zhao



Education and Clerkships

J.D., Washington University in St. Louis School of Law, 2014

B.A., Chemistry (biochemistry) and Psychology, Minor in Business, Washington University in St. Louis, 2009


California, 2015

District of Columbia, 2017


Chinese (Mandarin)



Yifang Zhao is an associate in the Intellectual Property Litigation Practice Group in the Washington, D.C. office of Haynes and Boone. In addition to engaging in various issues in patent infringement, trade secret misappropriation, and USPTO proceedings, her practice focuses on intellectual property issues related to pharmaceutical development and commercialization, from pre-suit analysis to litigation under the Hatch-Waxman Act.

Yifang has also managed patent portfolios for biotech companies, drafted patent applications and response to PTO communications, and analyzed validity and infringement issues relating to utility and design patents and trademarks.

Prior to law school, Yifang had significant experience in the field of cardiovascular extracellular protein research, and worked as a research scientist for a multinational agrochemical biotechnology corporation. She also volunteered in Tibet, worked, and studied in Asia and Europe.

Intellectual Property


The Bitter and the Sweet: Potential Split on the Constitutionality of Inter Partes Patent Review

Is a defeated patentee at Inter Partes Review an embittered citizen whose private rights were taken without due process by a government agency lacking requisite Article III guarantees of impartiality? Or is the public getting a sweet deal when the Patent Trials and Appeals Board (PTAB) eliminates or revokes a public right that was wrongfully granted in the first place? The Supreme Court wrestled with the constitutionality of Inter Partes Review during oral argument on Monday morning, and the Justices’ questions from the bench suggested rather strong differences of opinion but provided no clear insights on how the Court would rule.


IP Beacon

The IP Beacon

The IP Beacon is a Haynes and Boone Newsletter highlighting current issues and trends in Intellectual Property Law. Read the latest issue...


Biotechnology | Haynes and Boone, LLP

The Biologics Tango: Reading Tea Leaves on the Patent Dance and Pre-Marketing Notice Requirements

On Wednesday, April 26, 2017, the Supreme Court heard oral argument in Sandoz Inc. v. Amgen Inc. et al., a landmark case that many hope will provide clarity and guidance for consumers and the pharmaceutical industry on the regulatory approval pathway for biosimilar drugs under the Biologics Price Competition and Innovation Act of 2009.

Email Disclaimer